Global Multiple Sclerosis Therapeutics Market
The Global Multiple Sclerosis Therapeutics Market, by Drug Class (Antineoplastic Agents, Beta Interferon, Monoclonal Antibodies, and Corticosteroids), by Route of Administration (Injection and Oral), by Distribution Channel (e-Commerce, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa) had a market valuation of US$ 19,653.7 million in 2016 and is estimated to grow at a CAGR of 2.5 percent during the forecast period (2017 – 2025).
Get Your FREE Sample Copy of the Multiple Sclerosis Therapeutics Market Report 2021
With the projected introduction of promising pipeline candidates, the global multiple sclerosis therapeutics market is expected to gain considerable traction throughout the forecast period. Drug discovery is being prioritized by market participants in order to enhance the pipeline clinical trials and accelerate the supply of novel medicines to patients with multiple sclerosis, therefore expanding the global multiple sclerosis therapeutics market during the forecast period. TG Therapeutics, Inc. and the US Food and Drug Administration (FDA) reached a deal in 2017 addressing the Special Protocol Assessment (SPA) of phase III clinical studies for TG-1101, an anti-D20 monoclonal antibody for the therapy of relapse forms of multiple sclerosis. The global multiple sclerosis therapeutics market is projected to be fueled by the release of innovative and highly effective B-cell targeted treatments, which have shown to be a viable therapeutic for multiple sclerosis management. Ocrevus, a humanized monoclonal antibody targeting B-cells with the CD20 molecule, was authorized by the FDA in 2017. Ocrevus is the only treatment for relapsing and primary progressive multiple sclerosis that has been authorized by the FDA.
In the global multiple sclerosis therapeutics market, companies are also pursuing an inorganic growth strategy. Sanofi SA paid a whopping US$ 20.1 billion to purchase Genzyme in 2011, obtaining access to Genzyme’s injectable medication Lemtrada, which was FDA approved in 2014 for the management of relapsing remitting multiple sclerosis. Actelion Ltd. began Phase III research of ponesimod, a selective S1P1 receptor modulator, in recurrent multiple sclerosis patients in 2015. Johnson & Johnson bought Actelion Ltd. in 2017, acquiring rights to a preclinical medication option and thereby increasing its product range. Collaborations with healthcare providers, patients, and researchers are expected to establish ways to share findings in order to improve care for people with MS, resulting in the development of novel therapeutics with improved safety profiles. iConquerMS was developed in 2014 by the Accelerated Cure Project for MS, Feinstein Kean Healthcare, and Complex Adaptive Systems.
Browse 35 Market Data Tables and 40 Figures spread through 148 Pages and in-depth TOC on “Multiple Sclerosis Therapeutics Market”- Global Forecast to 2025, by Drug Class (Antineoplastic Agents, Beta Interferon, Monoclonal Antibodies, and Corticosteroids), by Route of Administration (Injection and Oral), by Distribution Channel (e-Commerce, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa)
View Press Release For More Information
Key Takeaways
Due to the large untapped market and rising government activities to combat the illness in Asia Pacific, Latin America, the Middle East, and Africa, the global multiple sclerosis therapeutics market is anticipated to grow at a CAGR of 2.5 percent during the forecast period.
Corticosteroids are the most popular medication class, owing to the benefits provided by the pharmaceuticals, which include a reduced risk of adverse effects and a larger number of drug candidates in the makers’ product range.
The injectable category has a prominent position in the global multiple sclerosis therapeutics market due to greater medical recommendations since medicines taken through this route have an immediate mode of action.
Key companies contributing in the global multiple sclerosis therapeutics market are Sanofi S.A., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, AbbVie, Inc., Merck & Co., Inc., Biogen Idec, and Bayer AG.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1310
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- Alternative Therapies
- Pipeline Analysis
- Supply Chain Analysis
- PEST Analysis
- Epidemiology
- Market Dynamics
- Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Antineoplastic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- E-Commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Request for Analysis of COVID-19 Impact on Multiple Sclerosis Therapeutics Market – https://www.coherentmarketinsights.com/insight/request-pdf/1310
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837